CNX Therapeutics is a UK-based pharmaceutical platform focused on providing life changing medicines within specialty therapeutic areas such as those targeting the central nervous system.
The business was formed in August 2021 when Inflexion acquired Sunovion Pharmaceuticals Europe’s operations including the pan-European license to supply LATUDA®, a drug used in the treatment of Schizophrenia.
The Inflexion difference
With substantial experience in successfully executing carve-outs, Inflexion will draw upon its healthcare expertise to establish CNX Therapeutics as a standalone business. We will support CNX Therapeutics to build its product portfolio to develop a scaled European platform focused on hospital and central nervous system therapies that stand to benefit from its existing infrastructure and capabilities.
We’re excited to be entering a new stage of growth and development for CNX Therapeutics. We look forward to working with Inflexion and drawing on their relevant experience in our sector to build a specialised European pharmaceuticals platform.
CEO, CNX Therapeutics